CoChat

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects

Open access
Palmiero, Giuseppe, Cesaro, Arturo, Vetrano, Erica, Pafundi, Pia Clara, Galiero, Raffaele, Caturano, Alfredo, Moscarella, Elisabetta, Gragnano, Felice, Salvatore, Teresa, Rinaldi, Luca, Calabrò, Paolo, Sasso, Ferdinando Carlo · 2021 · International Journal of Molecular Sciences
Cited by 110

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more in the elderly. Although, in T2DM, both hyperglycemia and the proinflammatory status induced by insulin resistance are crucial in cardiac function impairment, SGLT2i cardioprotective mechanisms against HF are several. In particular, these beneficial effects seem attributable to the significant reduction of intracellular sodium levels, well-known to exert a cardioprotective role in the prevention of oxidative stress and consequent cardiomyocyte death. From a molecular perspective, patients’ exposure to gliflozins’ treatment mimics nutrient and oxygen deprivation, with consequent autophagy stimulation. This allows to maintain the cellular homeostasis through different degradative pathways. Thus, since their introduction in the clinical practice, the hypotheses on SGLT2i mechanisms of action have changed: from simple glycosuric drugs, with consequent glucose lowering, erythropoiesis enhancing and ketogenesis stimulating, to intracellular sodium-lowering molecules. This provides their consequent cardioprotective effect, which justifies its significant reduction in CV events, especially in populations at higher risk. Finally, the updated clinical evidence of SGLT2i benefits on HF was summarized. Thus, this review aimed to analyze the cardioprotective mechanisms of sodium glucose transporter 2 inhibitors (SGLT2i) in patients with HF, as well as their clinical impact on cardiovascular events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22115863

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 122

  1. Shah, 2015, Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1·9 million people, Lancet Diabetes Endocrinol., 3, 105, 10.1016/S2213-8587(14)70219-0 · DOI · Paper page
  2. Bertoni, 2004, Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes, Diabetes Care, 27, 699, 10.2337/diacare.27.3.699 · DOI · Paper page
  3. Gresele, 2021, Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: From the START Antiplatelet registry, Int. J. Cardiol., 327, 176, 10.1016/j.ijcard.2020.10.079 · DOI
  4. Zhang, 2017, Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction, Am. J. Cardiol., 119, 1815, 10.1016/j.amjcard.2017.03.005 · DOI
  5. Clark, 2018, In-hospital worsening heart failure: A clinically relevant endpoint?, ESC Heart Fail., 5, 9, 10.1002/ehf2.12195 · DOI
  6. Corrao, 2014, Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study, Eur. J. Intern. Med., 25, 617, 10.1016/j.ejim.2014.06.027 · DOI
  7. Marcucci, 2016, REPOSI Investigators Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients, J. Gerontol. Ser. Boil. Sci. Med Sci., 72, 395
  8. Hwang, 2017, Effect of US Food and Drug Administration’s Cardiovascular Safety Guidance on Diabetes Drug Development, Clin. Pharmacol. Ther., 102, 290, 10.1002/cpt.705 · DOI
  9. Custodio, 2018, SGLT2 inhibition and heart failure—current concepts, Heart Fail. Rev., 23, 409, 10.1007/s10741-018-9703-2 · DOI
  10. Rubler, 1972, New type of cardiomyopathy associated with diabetic glomerulosclerosis, Am. J. Cardiol., 30, 595, 10.1016/0002-9149(72)90595-4 · DOI · Paper page
  11. Tate, 2017, Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat, Diabetes Vasc. Dis. Res., 14, 423, 10.1177/1479164117710390 · DOI
  12. Cesaro, 2020, Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition, BioFactors, 46, 367, 10.1002/biof.1619 · DOI
  13. Iribarren, 2001, Glycemic Control and Heart Failure Among Adult Patients With Diabetes, Circulation, 103, 2668, 10.1161/01.CIR.103.22.2668 · DOI · Paper page
  14. Waddingham, 2015, Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy, World J. Diabetes, 6, 943, 10.4239/wjd.v6.i7.943 · DOI · Paper page
  15. Qin, 2017, Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications, Pharmacol. Res., 116, 45, 10.1016/j.phrs.2016.12.016 · DOI
  16. Ma, 2016, Comparative Proteomics Reveals Dysregulated Mitochondrial O-GlcNAcylation in Diabetic Hearts, J. Proteome Res., 15, 2254, 10.1021/acs.jproteome.6b00250 · DOI
  17. Basta, 2004, Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes, Cardiovasc. Res., 63, 582, 10.1016/j.cardiores.2004.05.001 · DOI · Paper page
  18. Erqou, 2013, Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: Systematic review and meta-analysis, Eur. J. Heart Fail., 15, 185, 10.1093/eurjhf/hfs156 · DOI · Paper page
  19. Kristensen, 2017, Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation, Circ. Heart Fail., 10, 4409, 10.1161/CIRCHEARTFAILURE.117.004409 · DOI · Paper page
  20. Huynh, 2014, Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways, Pharmacol. Ther., 142, 375, 10.1016/j.pharmthera.2014.01.003 · DOI · Paper page
  21. Tate, 2017, Are targeted therapies for diabetic cardiomyopathy on the horizon?, Clin. Sci., 131, 897, 10.1042/CS20160491 · DOI
  22. Marfella, 2012, Tight Glycemic Control May Increase Regenerative Potential of Myocardium during Acute Infarction, J. Clin. Endocrinol. Metab., 97, 933, 10.1210/jc.2011-2037 · DOI · Paper page
  23. Marfella, 2012, Peri-Procedural Tight Glycemic Control during Early Percutaneous Coronary Intervention Is Associated with a Lower Rate of In-Stent Restenosis in Patients with Acute ST-Elevation Myocardial Infarction, J. Clin. Endocrinol. Metab., 97, 2862, 10.1210/jc.2012-1364 · DOI · Paper page
  24. Sasso, 2018, Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes, J. Diabetes Res., 2018, 1, 10.1155/2018/3106056 · DOI · Paper page
  25. Caturano, 2019, Metformin for Type 2 Diabetes, JAMA, 322, 1312, 10.1001/jama.2019.11489 · DOI
  26. Sasso, 1999, Cochlear dysfunction in type 2 diabetes: A complication independent of neuropathy and acute hyperglycemia, Metabolism., 48, 1346, 10.1016/S0026-0495(99)90141-5 · DOI · Paper page
  27. Sasso, 2018, Applicability of telemedicine in the screening of diabetic retinopathy (DR): The first multicentre study in Italy. The No Blind Study, Diabetes/Metabolism Res. Rev., 35, e3113, 10.1002/dmrr.3113 · DOI · Paper page
  28. Zhang, 2020, Oxidative stress and diabetes: Antioxidative strategies, Front. Med., 14, 583, 10.1007/s11684-019-0729-1 · DOI · Paper page
  29. Brancaccio, M., Mennitti, C., Cesaro, A., Fimiani, F., Moscarella, E., Caiazza, M., Gragnano, F., Ranieri, A., D’Alicandro, G., and Tinto, N. (2020). Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. Int. J. Environ. Res. Public Health, 17. · DOI
  30. Huynh, 2013, Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice, Free. Radic. Biol. Med., 60, 307, 10.1016/j.freeradbiomed.2013.02.021 · DOI
  31. Packer, 2018, Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis, Diabetes Obes. Metab., 20, 1361, 10.1111/dom.13229 · DOI
  32. Hsieh, 2014, Shear-induced endothelial mechanotransduction: The interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications, J. Biomed. Sci., 21, 3, 10.1186/1423-0127-21-3 · DOI · Paper page
  33. Kumrić, M., Borovac, J., Kurir, T., and Božić, J. (2021). Clinical Implications of Uric Acid in Heart Failure: A Comprehensive Review. Life, 11. · DOI
  34. Zafar, 2019, Metabolism of the failing heart and the impact of SGLT2 inhibitors, Expert Opin. Drug Metab. Toxicol., 15, 275, 10.1080/17425255.2019.1588886 · DOI
  35. Lopaschuk, 2010, Myocardial Fatty Acid Metabolism in Health and Disease, Physiol. Rev., 90, 207, 10.1152/physrev.00015.2009 · DOI · Paper page
  36. Landa, 1999, Effects of Autonomic Neuropathy on Coronary Blood Flow in Patients With Diabetes Mellitus, Circulation, 100, 813, 10.1161/01.CIR.100.8.813 · DOI · Paper page
  37. Masuo, 2010, Cardiovascular and renal complications of type 2 diabetes in obesity: Role of sympathetic nerve activity and insulin resistance, Curr. Diabetes Rev., 6, 58, 10.2174/157339910790909396 · DOI · Paper page
  38. Thomas, 2016, Type 2 Diabetes and Heart Failure: Challenges and Solutions, Curr. Cardiol. Rev., 12, 249, 10.2174/1573403X12666160606120254 · DOI · Paper page
  39. Campbell, 2011, Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease, Cardiovasc. Diabetol., 10, 80, 10.1186/1475-2840-10-80 · DOI · Paper page
  40. Cozzolino, 1996, The involvement of the opioid system in human obesity: A study in normal weight relatives of obese people, J. Clin. Endocrinol. Metab., 81, 713
  41. Cozzolino, 2004, Acute effects of β-endorphin on cardiovascular function in patients with mild to moderate chronic heart failure, Am. Heart J., 148, 530, 10.1016/j.ahj.2004.01.029 · DOI
  42. Khan, 2014, Management of Comorbid Diabetes Mellitus and Worsening Heart Failure, JAMA, 311, 2379, 10.1001/jama.2014.4115 · DOI
  43. Swoboda, P.P., McDiarmid, A.K., Erhayiem, B., Ripley, D.P., Dobson, L.E., Garg, P., Musa, T.A., Witte, K.K., Kearney, M.T., and Barth, J.H. (2017). Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. J. Am. Heart Assoc., 6. · DOI · Paper page
  44. Zelniker, 2020, Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors, J. Am. Coll. Cardiol., 75, 422, 10.1016/j.jacc.2019.11.031 · DOI · Paper page
  45. Lenti, 2019, Mortality rate and risk factors for gastrointestinal bleeding in elderly patients, Eur. J. Intern. Med., 61, 54, 10.1016/j.ejim.2018.11.003 · DOI
  46. Aubert, 2016, The Failing Heart Relies on Ketone Bodies as a Fuel, Circulation, 133, 698, 10.1161/CIRCULATIONAHA.115.017355 · DOI · Paper page
  47. Sowton, 2019, Metabolic Profiling of the Diabetic Heart: Toward a Richer Picture, Front. Physiol., 10, 639, 10.3389/fphys.2019.00639 · DOI
  48. Nielsen, 2019, Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients, Circulation, 139, 2129, 10.1161/CIRCULATIONAHA.118.036459 · DOI · Paper page
  49. Horton, 2019, The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense, JCI Insight, 4, 124079, 10.1172/jci.insight.124079 · DOI · Paper page
  50. Rajeev, 2015, SGLT2 inhibition and ketoacidosis—should we be concerned?, Br. J. Diabetes Vasc. Dis., 15, 155, 10.15277/bjdvd.2015.047 · DOI
  51. Verma, 2018, Empagliflozin Increases Cardiac Energy Production in Diabetes, JACC Basic Transl. Sci., 3, 575, 10.1016/j.jacbts.2018.07.006 · DOI · Paper page
  52. Daniele, 2017, Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients, Diabetes Obes. Metab., 19, 809, 10.1111/dom.12881 · DOI
  53. Antonio, 2019, Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics, J. Am. Coll. Cardiol., 73, 1931, 10.1016/j.jacc.2019.01.056 · DOI · Paper page
  54. Kappel, 2017, Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease, Circulation, 136, 969, 10.1161/CIRCULATIONAHA.117.029166 · DOI
  55. Goonasekera, 2012, Decreased cardiac L-type Ca2+ channel activity induces hypertrophy and heart failure in mice, J. Clin. Investig., 122, 280, 10.1172/JCI58227 · DOI · Paper page
  56. Lytvyn, 2017, Sodium Glucose Cotransporter-2 Inhibition in Heart Failure, Circulation, 136, 1643, 10.1161/CIRCULATIONAHA.117.030012 · DOI · Paper page
  57. Lambert, 2015, Intracellular Na + Concentration ([Na + ] i) Is Elevated in Diabetic Hearts Due to Enhanced Na+ Glucose Cotransport, J. Am. Heart Assoc., 4, e002183, 10.1161/JAHA.115.002183 · DOI · Paper page
  58. Kohlhaas, 2010, Elevated Cytosolic Na+ Increases Mitochondrial Formation of Reactive Oxygen Species in Failing Cardiac Myocytes, Circulation, 121, 1606, 10.1161/CIRCULATIONAHA.109.914911 · DOI · Paper page
  59. Banerjee, 2009, SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states, Cardiovasc. Res., 84, 111, 10.1093/cvr/cvp190 · DOI · Paper page
  60. Baartscheer, 2017, Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits, Diabetologia, 60, 568, 10.1007/s00125-016-4134-x · DOI · Paper page
  61. Uthman, 2018, Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation, Diabetologia, 61, 722, 10.1007/s00125-017-4509-7 · DOI · Paper page
  62. Packer, 2017, Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients with Heart Failure, JAMA Cardiol., 2, 1025, 10.1001/jamacardio.2017.2275 · DOI · Paper page
  63. Karmazyn, 2013, NHE-1: Still a viable therapeutic target, J. Mol. Cell. Cardiol., 61, 77, 10.1016/j.yjmcc.2013.02.006 · DOI
  64. Krishnan, 2009, Hyperuricemia and Incident Heart Failure, Circ. Heart Fail., 2, 556, 10.1161/CIRCHEARTFAILURE.108.797662 · DOI
  65. Saydah, 2004, Poor Control of Risk Factors for Vascular Disease among Adults With Previously Diagnosed Diabetes, JAMA, 291, 335, 10.1001/jama.291.3.335 · DOI · Paper page
  66. Ghantous, 2015, Differential Role of Leptin and Adiponectin in Cardiovascular System, Int. J. Endocrinol., 2015, 1, 10.1155/2015/534320 · DOI · Paper page
  67. Sasso, 2019, Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: The prospective AIRE Study, Cardiovasc. Diabetol., 18, 1, 10.1186/s12933-019-0826-0 · DOI · Paper page
  68. Schulze, 2003, Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure, Eur. J. Heart Fail., 5, 33, 10.1016/S1388-9842(02)00177-0 · DOI · Paper page
  69. Wu, 2019, Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes, Horm. Metab. Res., 51, 487, 10.1055/a-0958-2441 · DOI · Paper page
  70. Garvey, 2018, Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes, Metabolism., 85, 32, 10.1016/j.metabol.2018.02.002 · DOI · Paper page
  71. Sato, 2018, The effect of dapagliflozin treatment on epicardial adipose tissue volume, Cardiovasc. Diabetol., 17, 1, 10.1186/s12933-017-0658-8 · DOI · Paper page
  72. Esposito, 2007, Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: Role of tumor necrosis factor-α, Nutr. Metab. Cardiovasc. Dis., 17, 274, 10.1016/j.numecd.2005.11.014 · DOI
  73. Marfella, 2007, The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes, Cardiovasc. Diabetol., 6, 35, 10.1186/1475-2840-6-35 · DOI · Paper page
  74. Marfella, 2011, Innate Immune Activity in Plaque of Patients with Untreated andl-Thyroxine-Treated Subclinical Hypothyroidism, J. Clin. Endocrinol. Metab., 96, 1015, 10.1210/jc.2010-1382 · DOI · Paper page
  75. Torella, 2014, Carbonic Anhydrase Activation Is Associated With Worsened Pathological Remodeling in Human Ischemic Diabetic Cardiomyopathy, J. Am. Heart Assoc., 3, e000434, 10.1161/JAHA.113.000434 · DOI · Paper page
  76. Storgaard, H., Gluud, L.L., Bennett, C., Grøndahl, M.F., Christensen, M.B., Knop, F.K., and Vilsbøll, T. (2016). Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE, 11. · DOI · Paper page
  77. Tsimihodimos, 2018, SGLT-2 inhibitors: Pharmacokinetics characteristics and effects on lipids, Expert Opin. Drug Metab. Toxicol., 14, 1
  78. Haffner, 2003, American Diabetes Association Management of Dyslipidemia in Adults with Diabetes, Diabetes Care, 26, S83, 10.2337/diacare.26.2007.S83 · DOI · Paper page
  79. Zaccardi, 2016, Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis, Diabetes Obes. Metab., 18, 783, 10.1111/dom.12670 · DOI · Paper page
  80. Moscarella, 2019, Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry), Am. J. Cardiol., 124, 1662, 10.1016/j.amjcard.2019.08.030 · DOI
  81. Lopaschuk, 2020, Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors, JACC Basic Transl. Sci., 5, 632, 10.1016/j.jacbts.2020.02.004 · DOI · Paper page
  82. Gharaibeh, 2019, SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: Pathophysiology, clinical outcomes, and future directions, Diabetes Metab. Syndr. Obesity Targets Ther., 12, 1001, 10.2147/DMSO.S212715 · DOI
  83. Scheen, 2019, Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications, Diabetes Metab., 45, 213, 10.1016/j.diabet.2019.01.008 · DOI · Paper page
  84. Targher, 2020, NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications, Gut, 69, 1691, 10.1136/gutjnl-2020-320622 · DOI · Paper page
  85. Rinaldi, 2015, Effect of anti-oxidant agents in patients with hepato-cellular diseases, Eur. Rev. Med. Pharmacol. Sci., 19, 3993
  86. Rinaldi, 2016, Antioxidant diet and genotyping as tools for the prevention of liver disease, Eur. Rev. Med Pharmacol. Sci., 20, 5155
  87. Tromp, 2019, Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction, Diabetes Care, 42, 1792, 10.2337/dc18-2515 · DOI
  88. Zelniker, 2020, Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors, J. Am. Coll. Cardiol., 75, 435, 10.1016/j.jacc.2019.11.036 · DOI
  89. Baker, 2017, Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis, J. Am. Heart Assoc., 6, e005686, 10.1161/JAHA.117.005686 · DOI · Paper page
  90. Solini, 2017, Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study, Cardiovasc. Diabetol., 16, 1, 10.1186/s12933-017-0621-8 · DOI · Paper page
  91. Sugiyama, 2018, The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus, Intern. Med., 57, 2147, 10.2169/internalmedicine.0701-17 · DOI
  92. Tentolouris, 2020, Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice, Curr. Med. Chem., 27, 1089, 10.2174/0929867326666190119154152 · DOI
  93. Striepe, 2017, Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus, Circulation, 136, 1167, 10.1161/CIRCULATIONAHA.117.029529 · DOI · Paper page
  94. Ott, 2017, A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation, Cardiovasc. Diabetol., 16, 26, 10.1186/s12933-017-0510-1 · DOI · Paper page
  95. Karg, 2018, SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: A randomised controlled trial, Cardiovasc. Diabetol., 17, 1, 10.1186/s12933-017-0654-z · DOI · Paper page
  96. Kimura, 2016, Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure, Circ. J., 80, 2277, 10.1253/circj.CJ-16-0780 · DOI
  97. Giordano, 2017, Seasonal variations of hyponatremia in the emergency department: Age-related changes, Am. J. Emerg. Med., 35, 749, 10.1016/j.ajem.2017.01.018 · DOI
  98. Verma, 2017, The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition, JAMA Cardiol., 2, 939, 10.1001/jamacardio.2017.1891 · DOI · Paper page
  99. Sattar, 2016, SGLT2 Inhibition and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms?, Diabetologia, 59, 1333, 10.1007/s00125-016-3956-x · DOI · Paper page
  100. Aoyagi, T., and Matsui, T. (2012). The Cardiomyocyte as a Source of Cytokines in Cardiac Injury. J. Cell Sci. Ther., s5. · DOI
  101. Xu, 2017, SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice, EBioMedicine, 20, 137, 10.1016/j.ebiom.2017.05.028 · DOI · Paper page
  102. Bonnet, 2018, Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease, Diabetes Metab., 44, 457, 10.1016/j.diabet.2018.09.005 · DOI · Paper page
  103. Paulus, 2020, Unfolding Discoveries in Heart Failure, N. Engl. J. Med., 382, 679, 10.1056/NEJMcibr1913825 · DOI · Paper page
  104. Schiattarella, 2019, Nitrosative stress drives heart failure with preserved ejection fraction, Nat. Cell Biol., 568, 351
  105. Lee, 2017, Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts, Free. Radic. Biol. Med., 104, 298, 10.1016/j.freeradbiomed.2017.01.035 · DOI · Paper page
  106. Kang, 2020, Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results, Can. J. Cardiol., 36, 543, 10.1016/j.cjca.2019.08.033 · DOI · Paper page
  107. Lim, 2009, AMPK as a mediator of hormonal signalling, J. Mol. Endocrinol., 44, 87, 10.1677/JME-09-0063 · DOI · Paper page
  108. Lu, 2020, Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway, Mol. Cell. Endocrinol., 501, 110642, 10.1016/j.mce.2019.110642 · DOI
  109. Li, 2019, SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart, Cardiovasc. Diabetol., 18, 1, 10.1186/s12933-019-0816-2 · DOI · Paper page
  110. Chen, 2020, The association between SGLT2 inhibitors and new-onset arrhythmias: A nationwide population-based longitudinal cohort study, Cardiovasc. Diabetol., 19, 73, 10.1186/s12933-020-01048-x · DOI
  111. Santulli, 2018, Cardioprotective effects of autophagy: Eat your heart out, heart failure!, Sci. Transl. Med., 10, 462, 10.1126/scitranslmed.aau0462 · doi:10.1126/scitranslmed.aau0462
  112. Luo, 2019, Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress, Int. J. Mol. Med., 43, 2033
  113. Packer, 2020, Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors, Eur. J. Heart Fail., 22, 618, 10.1002/ejhf.1732 · DOI
  114. Hawley, 2016, The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels, Diabetes, 65, 2784, 10.2337/db16-0058 · DOI · Paper page
  115. Wilding, 2018, SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice, Diabetes Ther., 9, 1757, 10.1007/s13300-018-0471-8 · DOI · Paper page
  116. Figtree, 2018, Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus, Circulation, 138, 458, 10.1161/CIRCULATIONAHA.118.034222 · DOI · Paper page
  117. Coats, 2020, European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure, Eur. J. Heart Fail., 22, 196, 10.1002/ejhf.1673 · DOI · Paper page
  118. Fragasso, 2020, Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure, Eur. J. Heart Fail., 22, 1984, 10.1002/ejhf.2026 · DOI
  119. Mancini, 2021, Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction, J. Am. Coll. Cardiol., 77, 243, 10.1016/j.jacc.2020.11.008 · DOI · Paper page
  120. Damman, 2020, Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF), Eur. J. Heart Fail., 22, 713, 10.1002/ejhf.1713 · DOI · Paper page
  121. Anker, 2019, Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: Rationale for and design of the EMPEROR-Preserved Trial, Eur. J. Heart Fail., 21, 1279, 10.1002/ejhf.1596 · DOI · Paper page
  122. Minutolo, 2018, Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: Pooled analysis of four cohort studies, Nephrol. Dial. Transplant., 33, 1942, 10.1093/ndt/gfy032 · DOI

Cited by

See all 110

Metadata

Authors
Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P. C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., Rinaldi, L., Calabrò, P., & Sasso, F. C.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-05-30
Volume
22
Issue
11
Pages
5863
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3165814139
Cited by
110
References
48
FWCI
13.24
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. https://app.cochat.ai/papers/10.3390/ijms22115863
The paper
Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P. C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., Rinaldi, L., Calabrò, P., & Sasso, F. C. (2021). Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22115863

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.